Tibulizumab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Sclerosis (SSc)
Conditions
Systemic Sclerosis (SSc), Scleroderma
Trial Timeline
Feb 6, 2025 → Jan 1, 2028
NCT ID
NCT06843239About Tibulizumab
Tibulizumab is a phase 2 stage product being developed by Zura Bio for Systemic Sclerosis (SSc). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06843239. Target conditions include Systemic Sclerosis (SSc), Scleroderma.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Sclerosis (SSc) were approved
Approved (10) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06843239 | Phase 2 | Recruiting |
Competing Products
20 competing products in Systemic Sclerosis (SSc)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 32 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 35 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 21 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 26 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| E6742 | Eisai | Phase 1/2 | 32 |
| KHK4827 | Kyowa Kirin | Phase 1 | 29 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 40 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 32 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 40 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 27 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 32 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 29 |